{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T18:16:39Z","timestamp":1773425799088,"version":"3.50.1"},"reference-count":17,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"David Meats"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Bone"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1016\/j.bone.2011.10.018","type":"journal-article","created":{"date-parts":[[2011,10,27]],"date-time":"2011-10-27T08:42:50Z","timestamp":1319704970000},"page":"161-164","source":"Crossref","is-referenced-by-count":27,"title":["Teriparatide and the risk of nonvertebral fractures in women with postmenopausal osteoporosis"],"prefix":"10.1016","volume":"50","author":[{"given":"JH","family":"Krege","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X","family":"Wan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2011.10.018_bb0005","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1359\/jbmr.2003.18.11.1932","article-title":"Recombinant human parathyroid hormone (1\u201334) [teriparatide] improves both cortical and cancellous bone structure","volume":"18","author":"Jiang","year":"2003","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2011.10.018_bb0010","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1359\/JBMR.050105","article-title":"Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis","volume":"20","author":"Chen","year":"2005","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2011.10.018_bb0015","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1359\/jbmr.061011","article-title":"Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis","volume":"22","author":"Keaveny","year":"2007","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2011.10.018_bb0020","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1359\/jbmr.090416","article-title":"Improvements in vertebral body strength under teriparatide treatment assessed in vivo by finite element analysis: results from the EUROFORS study","volume":"24","author":"Graeff","year":"2009","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2011.10.018_bb0025","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1\u201334) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bone.2011.10.018_bb0030","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1185\/03007990902790993","article-title":"Teriparatide vertebral fracture risk reduction determined by quantitative and qualitative radiographic assessment","volume":"25","author":"Prevrhal","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.bone.2011.10.018_bb0035","unstructured":"Division of Metabolic and Endocrine Drug Products. Guidelines for preclinical and clinical evaluation of agents used in the prevention or treatment of postmenopausal osteoporosis. Food and Drug Administration. 1994. Available at: https:\/\/www.fda.gov. Accessed 26 January 2011."},{"key":"10.1016\/j.bone.2011.10.018_bb0040","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.bone.2011.10.018_bb0045","unstructured":"EMA guideline on the evaluation of medicinal products in the treatment of primary osteoporosis, 2006. Doc. Ref. CMP\/EWP\/552\/95\/ Rev. 2. Available at http:\/\/www.ema.europa.eu. Accessed 26 January 2011."},{"key":"10.1016\/j.bone.2011.10.018_bb0050","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","article-title":"Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis","volume":"19","author":"Chesnut","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2011.10.018_bb0055","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","article-title":"Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group","volume":"11","author":"Reginster","year":"2000","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.bone.2011.10.018_bb0060","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","article-title":"Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial","volume":"280","author":"Cummings","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.bone.2011.10.018_bb0065","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"New Engl J Med"},{"key":"10.1016\/j.bone.2011.10.018_bb0070","unstructured":"European Medicines Agency. Forsteo label. Available at: http:\/\/www.emea.europoa.eu. Accessed: 26 January 2011."},{"key":"10.1016\/j.bone.2011.10.018_bb0075","series-title":"Bone health and osteoporosis: a report of the surgeon general. Office of the Surgeon General. Public Health Service","author":"US Department of Health and Human Services","year":"2004"},{"key":"10.1016\/j.bone.2011.10.018_bb0080","unstructured":"National Osteoporosis Foundation. Clinician's guide to prevention and treatment of osteoporosis. Washington, DC: National Osteoporosis Foundation. 2010. Available at: http:\/\/www.nof.org. Accessed: 3 March 2011."},{"key":"10.1016\/j.bone.2011.10.018_bb0085","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s00198-008-0766-0","article-title":"Relationship between duration of teriparatide therapy and clinical outcomes in postmenopausal women with osteoporosis","volume":"20","author":"Lindsay","year":"2009","journal-title":"Osteoporos Int"}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328211012981?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328211012981?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,28]],"date-time":"2018-11-28T23:51:29Z","timestamp":1543449089000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328211012981"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["S8756328211012981"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2011.10.018","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2012,1]]}}}